Abstract
A JAK2V617F‐negative polycythemia associated with low serum epo needs to be tested for an exon 12 JAK2 mutation. When negative, due to potential serious complications in PV, a next generation sequencing is necessary to rule out false negative results.
Keywords: erythrocytosis, Exon 12, JAK2, next generation sequencing, polycythemia vera
A JAK2V617F‐negative polycythemia associated with low serum epo needs to be tested for an exon 12 JAK2 mutation. When negative, due to potential serious complications in PV, a next generation sequencing is necessary to rule out false negative results.
1. INTRODUCTION
Nearly 98% of patients with polycythemia vera (PV) harbor a JAK2 mutation. In these individuals, the mutation is found either on the exon 14 (the classical JAK2V617F)1 or on exon 12 (in 95% and 3% of cases, respectively).2 In a small proportion, atypical mutations of JAK2 have been reported, including JAK2C618R, coexisting JAK2 V617F/C618R,3 and in some exceptional cases a mutation of CALR.4
Compared with JAK2 (V617F)‐positive PV patients, those with exon 12 mutations had significantly higher hemoglobin levels and lower platelet and leukocyte counts at diagnosis but similar incidence of thrombosis, myelofibrosis, leukemia, and death.5 Moreover, JAK2 exon 12 variation is generally detected at lower level than JAK2V617F.6
The exon 12 JAK2 mutations are variable and heterogeneous including deletions, insertions, and duplications.7, 8, 9 Techniques based on allele‐specific polymerase chain reaction (AS‐PCR) are therefore unsuitable. On the other hand, Sanger sequencing and pyrosequencing do not have sufficient sensitivity for screening in some cases, which is why High Resolution Melting (HRM), a molecular method based on real‐time polymerase chain reaction (PCR), is a method of choice for detecting abnormalities in exon 12 of JAK2. HRM analyzes the DNA fusion curves during a gradual increase in temperature, and it appears to be the most efficient current technique for detection of JAK2 exon 12 mutations10 because it is associated with high sensitivity and specificity HRM analysis provides aberrant melting curves indicating the presence of a mutation that must then be characterized using Sanger sequencing. However, reports indicate that cloning was required before sequencing because of low allelic burden in 40% of aberrant melting curves profiles.11, 12 Indeed, DNA sequencing can overlook mutations with allele frequencies below 15%. Consequently, false negative results are possible with Sanger sequencing even when it is associated with aberrant melting curves.
We report here a series of four patients with low allele burden of JAK2 exon 12 mutations initially considered as having idiopathic erythrocytosis due to false negative results on JAK2 exon 12 mutations. The false negatives had been performed using HRM technology but nothing had been observed with Sanger sequencing due to the low allelic burden. We used total blood samples but if we had bone marrow samples, we would have a higher variant allelic frequency.13
Over the past 3 years, more than 250 samples from French patients with idiopathic erythrocytosis (defined by either red cell mass > 125% or hematocrit > 60% in male or 56% in female) have been tested using next generation sequencing (NGS) analysis with a dedicated panel including genes involved in the regulation of hypoxia and erythropoietin pathways. Due to the high cost of this technique, patients previously underwent a process of clinical and biological validation in order to rule out obvious causes of polycythemia. The main causes of erythrocytosis had to be excluded in order to restrict the analysis to idiopathic erythrocytosis. In particular, the search for a JAK2 mutation on exons 12 and 14 had to be negative in order to rule out PV. Surprisingly, in our cohort, in 4 patients (3 men and 1 woman, mean age at diagnosis 65.75 years) low allele burden JAK2 exon 12 mutations were observed, though they were initially considered negative for this mutation in the local laboratory. We only found 4 patients with low exon 12 mutations and no other ones. Most of them (3/4) had a classical low EPO level and an isolated erythrocytosis. The hematocrit and EPO results of patient #2 are explained because of her age: 97 years old (Table 1). The mutations noted in these patients have been reported many times,7 but in our cases, the allele burden was only 6%‐13%, which is below the threshold of sensitivity for Sanger sequencing. Of note, no other mutation (including LNK, EPOR, HIF, VHL, or PHD2) was observed in the 4 patients.
Table 1.
Exon 12 mutation and VAF of 4 patients analyzed with NGS method
| ID | Age (y) | sex | WBC | PLT | Hematocrit % | RCM | EPO mIU/mL | NGS | VAF |
|---|---|---|---|---|---|---|---|---|---|
| Patient #1 | 56 | M | 14.4 | 330 | 64.5 | NA | 1.7 |
JAK2 exon 12 p.K539L |
8% |
| Patient #2 | 97 | F | 6.40 | 408 | 41a | NA | 9.4 |
JAK2 exon 12 p.E543‐D544del |
13% |
| Patient #3 | 57 | M | NA | NA | 53 | +57% | 0.6 |
JAK2 exon 12 p.N542‐E543del |
6% |
| Patient #4 | 53 | M | NA | NA | NA | +35% | 1 |
JAK2 exon 12 p.F537‐K539del‐insL |
13% |
The quite low hematocrit rate of patient #2 is explained because she was treated with hydroxyurea for a triple‐negative thrombocythemia when the JAK2 exon 12 was noted.
Once the presence of JAK2 exon 12 mutations was detected by NGS analysis, the diagnosis of PV was confirmed and the patients were treated using phlebotomy or cytoreductive therapy to prevent thrombotic events, the most frequent complication in PV. One patient had been experiencing recurrent venous thrombosis and was treated with new oral anticoagulants. If the diagnosis of PV had been made earlier, these thrombotic episodes could have been avoided, underlining the need for an accurate diagnosis, especially when erythrocytosis is associated with low EPO level.8 Our results also suggest that aberrant HRM curves should lead to the search for a mutation by Sanger sequencing. Because there is a potential for serious complications, NGS analysis should be recommended when a JAK2 exon 12 mutation is not detected in order to rule out PV with a low allele burden.
CONFLICT OF INTEREST
None declared.
AUTHOR CONTRIBUTIONS
AG and FG: wrote the manuscript; BA, VB, PM, and CG: performed analyses; SB and BG: revised the manuscript.
ACKNOWLEDGMENTS
This study was supported by grants from the ANR (PRTS 2015 "GenRED"); the labex GR‐Ex, reference ANR‐11‐LABX‐0051, and l'Association des Tulipes contre le cancer, Châlon sur Saône).
Geay A, Aral B, Bourgeois V, et al. Diagnosis of exon 12‐positive polycythemia vera rescued by NGS. Clin Case Rep. 2020;8:790–792. 10.1002/ccr3.2720
REFERENCES
- 1. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia. 2006;20(2):350‐353. [DOI] [PubMed] [Google Scholar]
- 2. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459‐468. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Warshawsky I, Mularo F, Hren C, Jakubowski M. Failure of the ipsogen mutascreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F. Blood. 2010;115(15):3175‐3176. [DOI] [PubMed] [Google Scholar]
- 4. Broséus J, Park J‐H, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2‐negative polycythemia vera. Blood. 2014;124(26):3964‐3966. [DOI] [PubMed] [Google Scholar]
- 5. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical feature of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117(10):2813‐2816. [DOI] [PubMed] [Google Scholar]
- 6. Theocharides A, Passweg JR, Medinger M, et al. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008;93(12):1890‐1893. [DOI] [PubMed] [Google Scholar]
- 7. James C, Ugo V, Le Couédic J‐P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144‐1148. [DOI] [PubMed] [Google Scholar]
- 8. Ugo V, Tondeur S, Menot M‐L, et al. Interlaboratory development and validation of a HRM method applied to the detection of JAK2 Exon 12 mutations in polycythemia vera patients. PLoS ONE. 2010;5(1):e8893. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status. Lancet. 2005;366(9501):1945‐1953. [DOI] [PubMed] [Google Scholar]
- 10. Carillo S, Henry L, Lippert E, et al. Nested high‐resolution melting curve analysis: a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations – clinical relevance in the monitoring of polycythemia. J Mol Diagn. 2011;13(3):263‐270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Rapado I, Grande S, Albizua E, et al. High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations. J Mol Diagn. 2009;11(2):155‐161. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Jones AV, Cross NC, White HE, et al. Rapid identification of JAK2 Exon 12 mutations using high resolution melting analysis. Haematologica. 2008;93(10):1560‐1564. [DOI] [PubMed] [Google Scholar]
- 13. Kjaer L, Westman M, Hasselbalch Riley C, et al. A highly sensitive quantitative real‐time PCR assay for determination of mutant JAK2 Exon 12 allele burden. PLoS ONE. 2012;7(3):e33100. [DOI] [PMC free article] [PubMed] [Google Scholar]